Bli medlem
Bli medlem

Du är här

2015-04-01

Basilea Pharmaceutica AG: Basilea in-licenses targeted cancer therapy

Basilea Pharmaceutica AG / Basilea in-licenses targeted cancer therapy.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
Basel, Switzerland, April 1, 2015

- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it has entered
into a license agreement for novel panRAF kinase inhibitors with a consortium
of organizations including The Institute of Cancer Research, London, Cancer
Research Technology, the Wellcome Trust and The University of Manchester.

The agreement grants Basilea exclusive worldwide rights to develop,
manufacture and commercialize novel panRAF kinase inhibitors which originate
from research at The Institute of Cancer Research by scientists funded by
Cancer Research UK and the Wellcome Trust. RAF kinases play an important role
in tumor cell proliferation. The oral, small molecule panRAF inhibitors
target BRAF and other growth pathways relied upon by resistant tumor cells.
These properties allow anti-cancer activity in a range of tumor models
including tumors resistant to anti-BRAF therapy associated with a number of
marketed anti-cancer drugs.[1] The lead compound is anticipated to start
clinical phase 1 testing in 2015.

Under the terms of the agreement, the consortium will lead clinical phase 1
development for the lead compound. Basilea will assume full operational
responsibility thereafter. The consortium receives an upfront payment and is
eligible to potential milestone payments on achievement of pre-specified
clinical, regulatory and commercial milestones, as well as tiered royalties
on future net sales.

Professor Caroline Springer, Professor of Biological Chemistry at The
Institute of Cancer Research, London, said: "I'm delighted by today's
announcement, which is excellent news for research into treatments for
drug-resistant cancers. The agreement provides the foundation for the
clinical development of this exciting new drug class. It is an important
milestone in efforts to tackle resistance to existing cancer therapies and
provide new options for cancer patients."

"We are excited about complementing our growing and maturing oncology pipeline
with this novel program including a lead compound expected to enter clinical
testing in 2015. The available data show that this novel class of panRAF
inhibitors are active in tumors which have developed resistance to currently
available RAF kinase inhibitors and have the potential to offer new treatment
options for melanoma as well as additional cancer indications," said Dr.
Laurenz Kellenberger, Basilea's Chief Scientific Officer.

About The Institute of Cancer Research, London

The Institute of Cancer Research, London, is one of the world's most
influential cancer research institutes. Scientists and clinicians at The
Institute of Cancer Research (ICR) are working every day to make a real
impact on cancer patients' lives. Through its unique partnership with The
Royal Marsden NHS Foundation Trust and "bench-to-bedside" approach, the ICR
is able to create and deliver results in a way that other institutions
cannot. Together the two organisations are rated in the top four cancer
centres globally. The ICR has an outstanding record of achievement dating
back more than 100 years. It provided the first convincing evidence that DNA
damage is the basic cause of cancer, laying the foundation for the now
universally accepted idea that cancer is a genetic disease. Today it leads
the world at isolating cancer-related genes and discovering new targeted
drugs for personalized cancer treatment. As a college of the University of
London, the ICR provides postgraduate higher education of international
distinction. It has charitable status and relies on support from partner
organisations, charities and the general public. The ICR's mission is to make
the discoveries that defeat cancer. For more information
visithttp://www.icr.ac.uk

About Cancer Research Technology

Cancer Research Technology (CRT) is a specialist commercialization and
development company, which aims to develop new discoveries in cancer research
for the benefit of cancer patients. CRT works closely with leading
international cancer scientists and their institutes to protect intellectual
property arising from their research and to establish links with commercial
partners. CRT facilitates the discovery, development and marketing of new
cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is
wholly owned by Cancer Research UK, the world's leading cancer charity
dedicated to saving lives through research. Further information about CRT can
be found atwww.cancertechnology.com.

About Cancer Research UK

Cancer Research UK is the world's leading cancer charity dedicated to saving
lives through research. Cancer Research UK's pioneering work into the
prevention, diagnosis and treatment of cancer has helped save millions of
lives. Cancer Research UK receives no government funding for its life-saving
research. Every step it makes towards beating cancer relies on every pound
donated. Cancer Research UK has been at the heart of the progress that has
already seen survival rates in the UK double in the last forty years. Today,
2 in 4 people survive cancer. Cancer Research UK's ambition is to accelerate
progress so that 3 in 4 people will survive cancer within the next 20 years.
Cancer Research UK supports research into all aspects of cancer through the
work of over 4,000 scientists, doctors and nurses. Together with its partners
and supporters, Cancer Research UK's vision is to bring forward the day when
all cancers are cured. For further information about Cancer Research UK's
work or to find out how to support the charity, please call +44 (0)300 123
1022 or visitwww.cancerresearchuk.org. Follow Cancer Research UK
onTwitterandFacebook.

About The University of Manchester

The University of Manchester, a member of the prestigious Russell Group of
British universities, is the largest and most popular university in the UK.
It has 20 academic schools and hundreds of specialist research groups
undertaking pioneering multi-disciplinary teaching and research of worldwide
significance. The University of Manchester is one of the UK's major research
institutions, rated fifth in the UK in terms of "research power", and has had
no fewer than 25 Nobel laureates either work or study there. The University
had an annual income of GBP 886 million in 2013/14. www.manchester.ac.uk

Cancer is one of The University of Manchester's research beacons - examples of
pioneering discoveries, interdisciplinary collaboration and cross-sector
partnerships that are tackling some of the biggest questions facing the
planet.http://www.manchester.ac.uk/research/beacons/cancer/

About Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to improving
health. It provides more than GBP 700 million a year to support bright minds
in science, the humanities and the social sciences, as well as education,
public engagement and the application of research to medicine. Its GBP 18
billion investment portfolio gives it the independence to support such
transformative work as the sequencing and understanding of the human genome,
research that established front-line drugs for malaria, and Wellcome
Collection, its free venue for the incurably curious that explores medicine,
life and art.

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment
options in the therapeutic areas of bacterial infections, fungal infections
and cancer. The company uses the integrated research, development and
commercial operations of its subsidiary Basilea Pharmaceutica International
Ltd. to develop and commercialize innovative pharmaceutical products to meet
the medical needs of patients with serious and life-threatening conditions.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed
on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at
Basilea's websitewww.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

-------------------------------------------------------------
| Media Relations Investor Relations |
| Peer Nils Schröder, PhD Barbara Zink, PhD, MBA |
| |
|Head Public Relations& Head Corporate Development |
|Corporate Communications |
|+41 61 606 1102 +41 61 606 1233 |
|media_relations@basilea.com investor_relations@basilea.com |
-------------------------------------------------------------
This press release can be downloaded fromwww.basilea.com.

References

[1] Girotti et al., Paradox-breaking RAF inhibitors that also target SRC are
effective in drug-resistant BRAF mutant melanoma, Cancer Cell 2015 (27),
85-96

Press release (PDF)
http://hugin.info/134390/R/1908073/679873.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire

HUG#1908073

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.